Daily briefing

OpenAI's AI agents now click through EHRs and payer portals for clinicians

Nov 18, 2026

Illustration: a clipboard with a checklist holds a paper with two checked boxes and a cursor pointing at the third box.

OpenAI on Nov. 16 opened AI agents that click, type and move between electronic health records and payer portals to clinicians and health systems, and said CVS Health and Cigna Healthcare already run them.

The agents draft orders, notes, patient replies and prior authorization requests for human review, and OpenAI said reviewers rated 99% of 325 inbox tasks clinically safe in its own unpublished evaluation. Health systems choose which actions the agents may take and can pause them, the company said.

Separately, the White House withdrew Dr. Heidi Overton's nomination to lead the FDA, a Pan American Health Organization committee confirmed that the U.S. has lost measles elimination status, and HHS finalized a HIPAA rule that halves the time practices have to answer patients' record requests.

  • WatchDeployment Nov 16, 2026

    OpenAI said health systems set which actions the agents may take and which steps need human review before submission.

    All physicians
    OpenAI on Nov. 16 made computer-use agents, which read screens, click and type across applications such as electronic health records and payer portals, available in ChatGPT for Healthcare, the free ChatGPT for Clinicians and its API. In a demonstration on synthetic data, an agent reviewed a back pain patient's notes and imaging, drafted an MRI order, an encounter note and a patient reply for clinician review, and prepared a prior authorization request. Reviewers rated 99% of 325 EHR inbox tasks completed by its GPT-6 Astra model as clinically safe, and physicians gave the top two helpfulness ratings in 93% of 646 assessments, according to OpenAI's own evaluation, which has not been peer reviewed. CVS Health said agents cleared a months-long document backlog over a weekend and handle system steps for tens of thousands of consults a day, and Cigna Healthcare said it moved from concept to deployment in under eight weeks, Becker's reported.
  • FYIRegulation Nov 17, 2026
    All physicians
    The Trump administration withdrew the nomination of Dr. Heidi Overton, a preventive care physician and former White House health policy adviser, as FDA commissioner on Nov. 17, a White House official and a source close to Overton told STAT. The move followed concerns that she lacked enough support from Republicans on the Senate Health, Education, Labor and Pensions Committee, which had been expected to vote on her nomination Nov. 18, STAT reported. Axios first reported the withdrawal.
    Source: STAT
  • WatchRegulation Nov 16, 2026

    Compliance is required 240 days after the rule is published in the Federal Register, according to the American Hospital Association.

    PracticesHospitals
    The HHS Office for Civil Rights on Nov. 16 finalized changes to the HIPAA Privacy Rule that cut the time covered entities have to respond to patients' requests for copies of their records to 15 days from 30, according to the American Hospital Association. Covered entities must post estimated fee schedules for copies on their websites and may not impose unreasonable identity verification, the AHA said. Patients may obtain electronic records through a personal health app when the covered entity can produce them in that form and may direct an electronic copy from an EHR to a person they designate, HHS said. Direct-treatment providers no longer need to seek a patient's written acknowledgment of the notice of privacy practices, and covered entities may disclose information to social services agencies and community organizations for care coordination. The rule takes effect 60 days after Federal Register publication; it was first proposed in 2021.
  • FYIIncident Nov 17, 2026
    All physicians
    A Pan American Health Organization committee found on Nov. 17 that the United States no longer has measles elimination status, STAT reported. The review turned on whether a chain of transmission that began in January 2025 lasted at least 12 months. The country has recorded more than 5,000 cases in 2026, the most since 1991, and 96% of infections were in people who were unvaccinated or of unknown status, according to STAT; states have reported 10 deaths this year while the CDC lists six. PAHO also found measles endemic again in Mexico and Bolivia, STAT reported. "Losing measles elimination status is a tragic loss for our country," said Dr. Susan Kansagra of the Association of State and Territorial Health Officials.
    Source: STAT
  • FYIRegulation Nov 17, 2026
    Primary careInternal medicine
    The FDA approved secukinumab (Cosentyx) 150 mg on Nov. 17 for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a steroid taper, making it the first IL-17 inhibitor for the disease, Novartis said. In the phase 3, double-blind, placebo-controlled REPLENISH trial across 27 countries, 40.5% of patients on 150 mg reached sustained remission at week 52 after a 24-week steroid taper, against 20.5% on placebo. Serious adverse events occurred in 15.9% versus 14.2%, urinary tract infections in 13% versus 7% and hypersensitivity reactions in 14% versus 9%, and one patient on secukinumab died of cryptococcal meningitis, the company said.
    Source: Novartis
  • FYIRegulation Nov 17, 2026
    The FDA cleared Medtronic's Hugo robotic-assisted surgery system on Nov. 17 for all upper abdominal general surgery, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection, plus inguinal hernia repair and appendectomy, the company said. Hugo had been cleared in the U.S. only for urologic procedures since December 2025. The newly cleared procedures account for about 3.5 million U.S. operations a year, more than half of soft tissue surgery, according to Medtronic. Johnson & Johnson's Ottava robot was authorized for general surgery in July, and Stryker agreed in October to distribute CMR Surgical's Versius in the U.S., MedTech Dive reported.
  • FYIRegulation Nov 16, 2026
    The FDA approved giredestrant (Wilserdly) with everolimus on Nov. 16 for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer that recurred during or after adjuvant endocrine therapy or progressed on at least one endocrine regimen for metastatic disease, Roche said. In the open-label phase 3 evERA trial in patients previously treated with a CDK4/6 inhibitor, the combination lowered the risk of progression or death 62% against standard endocrine therapy plus everolimus in the ESR1-mutated group (hazard ratio, 0.38; 95% CI, 0.27 to 0.54). Oral SERDs from Eli Lilly and AstraZeneca are also limited to ESR1-mutated disease, and an RBC Capital Markets note put Wilserdly's list price at $22,500 a month, BioPharma Dive reported. An FDA decision on adjuvant use is due Nov. 30, Roche said.

Latest news

  1. Medicare proposes requiring clinicians who bill Advantage plans to enroll in traditional Medicare and to report changes within 30 days
  2. Physicians' accuracy fell along with a failing AI's, and only one in eight noticed the tool breaking down, a randomized study finds
  3. Semaglutide lowered BMI 13.5% in children 6 to 11 with obesity, against a 2.7% rise on placebo, in a 68-week phase 3 trial

See all the latest news